CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Risk-reducing (prophylactic) mastectomy — Coverage Criteria

Defines coverage stance and supporting background for risk-reducing mastectomy for Medicare Advantage and commercial products; describes clinical context and coding for Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyRisk-reducing (prophylactic) mastectomy — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument individualized cancer risk assessment and provide counseling by a non-operating cancer-risk professional about alternatives and risks.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

coveredcoverage stance for product lines

19303example covered CPT code

bilateral/contralateralprocedure contexts

recommendedpreop counseling recommended

Coverage Criteria — Risk-reducing (Prophylactic) Mastectomy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered indications / clinical considerations

Risk-reducing mastectomy is covered for Medicare Advantage and Commercial Products; candidate selection should be based on individualized high-risk assessment and counseling.

Coverage prerequisites: Service is covered for Medicare Advantage Plans and Commercial Products when clinical decision-making supports risk-reducing mastectomy based on high-risk status (examples include known BRCA1/BRCA2 or other high-penetrance pathogenic variants, lobular carcinoma in situ, prior chest radiotherapy before age 30, or individualized high lifetime risk assessment), and after counseling about alternatives and risks by a non-operating cancer-risk professional.see background (high risk often considered >20% lifetime risk)

Benefits may vary by group/contract; verify member-specific benefits.

Provider Actions — Authorization, Counseling, and Alternatives

Prior Authorization

Prior Authorization and Covered Codes

Prior authorization is not applicable for risk-reducing mastectomy under these products. Risk-reducing mastectomy is a covered service for Medicare Advantage Plans and Commercial products per this policy.

Prior authorization: Not applicable
Coverage: Risk-reducing mastectomy covered for Medicare Advantage and Commercial products

Documentation Required

Preoperative Risk Assessment and Counseling

Documented individualized cancer-risk assessment and counseling are recommended prior to elective risk-reducing mastectomy. Risk assessment should consider family history, validated risk models (eg, Gail, BCSC), known pathogenic variants (BRCA1, BRCA2, TP53, PTEN, CDH1, etc.), prior chest radiation (especially before age 30), and lesions associated with increased cancer risk (eg, lobular carcinoma in situ). Counseling should be provided by a clinician or cancer-risk professional who is not the operating surgeon, and should include discussion of risks, benefits, cosmetic outcomes, and reconstruction options.

Document individualized cancer-risk assessment (family history, genetic test results, prior chest radiation, lesions such as LCIS)
Counseling by a non-operating cancer-risk professional required/strongly recommended
Discuss alternatives, cosmetic outcomes, and reconstruction

Note

Non-surgical Alternatives

Non-surgical alternatives to risk-reducing mastectomy should be part of shared decision-making. Alternatives include enhanced surveillance (eg, more frequent imaging and clinical exams) and chemoprevention where appropriate. The choice between surgery and non-surgical strategies should reflect individualized cancer risk estimates, patient values, and tolerance for residual risk.

Consider chemoprevention when clinically appropriate
Offer increased surveillance (imaging and clinical follow-up) as an alternative
Ensure shared decision-making incorporating individualized risk estimates

Billing Rule

Member Eligibility and Medical Necessity Impact on Payment

Payment and coverage determinations are governed by the member's specific benefits, subscriber/employer agreements, and applicable plan documents. Services that are not medically necessary or are non-covered per the member's benefit plan may be denied. Providers should verify member eligibility and benefits prior to scheduling procedures and inform members if services may not be covered; members may not be billed for non-covered services unless they provide written agreement in advance per participation agreements.

Verify member eligibility and benefits prior to authorization/scheduling
Payment governed by member subscriber agreement and employer agreement
Do not charge members for non-covered services unless informed and written consent obtained in advance

Background — Clinical Context

Risk-reducing (prophylactic) mastectomy is the surgical removal of breast tissue in the absence of an active breast malignancy with the clinical intent of lowering future breast cancer risk. It is considered for patients assessed to be at high lifetime risk — for example, those with known pathogenic variants such as BRCA1/BRCA2 or other high‑penetrance genes, a history of lobular carcinoma in situ (LCIS), or prior therapeutic chest radiotherapy before age 30. Candidate selection requires individualized risk estimation and counseling about alternatives (such as enhanced surveillance and chemoprevention) and the risks and benefits of surgery; counseling by a health professional other than the operating surgeon is recommended.

Definitions

Risk‑reducing mastectomy

DefinitionRemoval of the breast in the absence of malignant disease to reduce the risk of breast cancer occurrence.

PurposePerformed to lower future breast cancer risk in patients without current breast malignancy.

Typical lateralityTypically bilateral but may be unilateral in certain contexts (see CPM).

Contralateral risk‑reducing mastectomy (CPM)

DefinitionMastectomy performed on the opposite healthy breast in a patient with unilateral invasive cancer to reduce risk of cancer occurring in the contralateral breast.

TrendsUse of contralateral risk‑reducing mastectomy has increased in the U.S.; analyses show rising rates over time.

Clinical considerationsDecision informed by individualized risk assessment, patient tolerance for risk, cosmetic impacts, and alternatives such as surveillance or chemoprevention.

OpenPayer

Risk-reducing (prophylactic) mastectomy — Coverage Criteria

Coverage Criteria — Risk-reducing (Prophylactic) Mastectomy

Coding — Covered Codes and Risk Thresholds

Provider Actions — Authorization, Counseling, and Alternatives

Background — Clinical Context

Definitions